Junshi Biosciences and DotBio Announce Collaboration to Develop Next-Generation Antibody Therapy with DotBody Module
SHANGHAI, China and SINGAPORE, Jan. 05, 2022 (GLOBE NEWSWIRE) — Shanghai Junshi Biociences Co., Ltd (“Junshi Biosciences”, HKEX: 1877, SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, and DotBio Pte. Ltd (“DotBio”), a biotech company specialized in next generation antibody therapies, announced today that they have […]